- Record: found
- Abstract: found
- Article: not found
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Pan Feng Shang
1 ,
Joey Kwong ,
Zhi Ping Wang ,
Jinhui Tian ,
Lei Jiang ,
Kehu Yang ,
Zhong Jin Yue ,
Jun Qiang Tian
May 11 2011
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bladder cancer accounts for approximately 4.4% of adult malignancies, and approximately 80% of bladder cancer presents initially as transitional cell carcinoma that is confined to the urothelium (stage Ta) or lamina propria (stage T1). Intravesical administration of Bacillus Calmette-Guérin (BCG) and epirubicin (EPI) has been proven to reduce tumour recurrence and prevent or delay progression to muscle invasion and metastases. However, comparison of the effectiveness and safety of intravesical BCG and EPI in bladder cancer has yet to be explored.